How many studies have been conducted on Complement C1 Inhibitor Protein?

BiohacksAI has indexed 29 PubMed studies on Complement C1 Inhibitor Protein, including 2 randomized controlled trials (RCTs). 69% of studies involve human subjects.

What are the main research areas for Complement C1 Inhibitor Protein?

The primary research domains for Complement C1 Inhibitor Protein are 🫘 Kidney, 💪 Strength & Power, 🔬 Oncology. This is based on analysis of 29 PubMed studies using the BiohacksAI evidence platform.

BETABiohacksAI is a research tool for informational purposes only. All outputs are computational hypothesis candidates — not confirmed mechanisms, not medical advice, and not a substitute for professional medical judgment. Independent experimental validation is always required.

Complement C1 Inhibitor Protein

An endogenous 105-kDa plasma glycoprotein produced primarily by the LIVER and MONOCYTES. It inhibits a broad spectrum of proteases, including the COMPLEMENT C1R and the COMPLEMENT C1S proteases of the CLASSICAL COMPLEMENT PATHWAY, and the MANNOSE-BINDING PROTEIN-ASSOCIATED SERINE PROTEASES. C1-INH-deficient individuals suffer from HEREDITARY ANGIOEDEMA TYPES I AND II.

29+ PubMed studies analyzed · 2 RCTs · Evidence Score: 46.3

Research Domains

Complement C1 Inhibitor Protein has been studied across 4 research domains including 🫘 Kidney, 💪 Strength & Power, 🔬 Oncology, 🧬 Hormones. The primary research focus is 🫘 Kidney with 7% of studies addressing this area.

Loading evidence profile...

This evidence profile for Complement C1 Inhibitor Protein is generated deterministically from 29 PubMed-indexed studies. All data is corpus-verified with Merkle proofs. BiohacksAI does not provide medical advice. Always consult a healthcare professional before starting any supplement regimen.